Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Flexion Therapeutics (Nasdaq:FLXN) announced that CEO Michael Clayman will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available as an on-demand webcast starting at 7 a.m. ET on September 13 and can be accessed through the Flexion website. Flexion focuses on developing local therapies for musculoskeletal conditions, including osteoarthritis. For more details, visit Flexion's Investor Relations page.
- None.
- None.
BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
The presentation will be available through an on-demand webcast beginning at 7 a.m. ET on September 13, 2021, and will be accessible on the Flexion website at http://ir.flexiontherapeutics.com.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com.
Contact:
Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com
FAQ
When will Flexion Therapeutics participate in the H.C. Wainwright Global Investment Conference?
What time will the Flexion Therapeutics presentation be available?
Where can I watch the Flexion Therapeutics presentation?
What is Flexion Therapeutics focused on developing?
